Innovation Pharmaceuticals Inc (IPIX)

[damnthetorpedoes]

There are many people on this board who believe that Leo hit a grand slam when they bought the entire drug portfolio from the now bankrupt company called Polymedix.
Some think that many of the larger pharm and biotech's missed out but the truth is that it could be that decided to pass on what Polymedix had to offer.
Brilacidin had already been in a phase 2 study and appeared to show good therapeutic efficacy at low doses but 85 % of the patients had suffered with severe numbness and tingling, 5 dropped out and there was at least one severe untoward reaction.
The CEO,Mr. Nicholas Landekic was in the pharmaceutical field for over 25 years and had ties and connections to Bristol Myers Squibb as well as Johnson and Johnson.
Do you honestly believe that he would not have contacted these people and told them of this great opportunity?
No, I believe Leo should have stayed the course and they should pushed to trial Prurisol because it holds such great potential from the preclinical data.

As a former PYMX investor, I can respond to that.

"Brilacidin had already been in a phase 2 study and appeared to show good therapeutic efficacy at low doses but 85 % of the patients had suffered with severe numbness and tingling, 5 dropped out and there was at least one severe untoward reaction."
- Wrong! Numbness and tingling were characterized as mild and went away upon discontinuance, mostly at the end of the 5-day dosing regimen. In addition, analysis of the treated patients, including serum levels of Brilacidin, indicated a much shorter course of treatment at low dose levels would likely provide a full cure, thus minimizing the side effects.

"The CEO,Mr. Nicholas Landekic was in the pharmaceutical field for over 25 years and had ties and connections to Bristol Myers Squibb as well as Johnson and Johnson.
Do you honestly believe that he would not have contacted these people and told them of this great opportunity?"
- Yes, I believe either he would not have or that they refused to bargain with someone with his huge ego. Many times, Nick claimed Polymedix would "become the next Amgen". In reality, he pissed off so many both potential pharmaceutical partners and potential large investors that he alone was the primary reason for the company's ultimate failure. By the time the incompetent Board of Directors finally ousted him, it was way too late.

From the Brilacidin Fact Sheet:
"The most common adverse event experienced by patients in the study was numbness and tingling, felt by 65%-87% of treated patients. The majority of the cases were rated as mild and no patient discontinued due to just numbness and tingling. Excluding the numbness and tingling, the treatment-related adverse events were 9.6%, 5.6%, and 7.4% for the low, medium and high dose of bri-
lacidin vs. 10.9% for daptomycin. Eight patients discontinued treatment due to treatment-related adverse events. Three patients
that received brilacidin experienced a treatment-related serious adverse event Two of these patients discontinued treatment due
to hypertension (one medium dose and one high dose)."